cedrin
3a,5,5a,9b-tetrahydro-4,5-dihydroxy-9-methoxy-3,5a-dimethylnaphtho[1,2-b]furan-2,8(3H,4H)-dione
Identification
| Name | cedrin |
| IUPAC | 4,5-dihydroxy-9-methoxy-3,5a-dimethyl-3a,4,5,9b-tetrahydro-3H-benzo[g][1]benzofuran-2,8-dione |
| CAS Number | 6040-62-6 |
| FDA UNII | Search |
| Molecular Formula | C15 H18 O6 |
| Molecular Weight | 294.30366000 |
Regulatory
Physical Properties
| Assay | 95.00 to 100.00 |
| Food Chemicals Codex Listed | No |
| Boiling Point | 544.75 °C. @ 760.00 mm Hg (est) |
| Flash Point | 404.00 °F. TCC ( 206.70 °C. ) (est) |
| logP (o/w) | -1.049 (est) |
| Soluble in | water, 3.398e+005 mg/L @ 25 °C (est) |
No sensory data available
Safety Information
| Oral/Parenteral Toxicity | Not determined |
| Dermal Toxicity | Not determined |
| Inhalation Toxicity | Not determined |
GHS Classification
['GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)', 'GHS Label elements, including precautionary statements']
Safety in Use
| Category | natural substances and extractives |
| Recommendation for cedrin usage levels up to | not for fragrance use. |
| Recommendation for cedrin flavor usage levels up to | not for flavor use. |
No supplier data available
Potential Uses
Natural Occurrence
Synonyms
4,5-
dihydroxy-9-methoxy-3,5a-dimethyl-3a,4,5,9b-tetrahydro-3H-benzo[g][1]benzofuran-2,8-dione
naphtho(1,2-b)furan-2,8(3H,4H)-dione, 3a,5,5a,9b-tetrahydro-4,5-dihydroxy-9-methoxy-3,5a-dimethyl-
3a,5,5a,9b-
tetrahydro-4,5-dihydroxy-9-methoxy-3,5a-dimethyl naphtho(1,2-b)furan-2,8(3H,4H)-dione
3a,5,5a,9b-
tetrahydro-4,5-dihydroxy-9-methoxy-3,5a-dimethylnaphtho[1,2-b]furan-2,8(3H,4H)-dione
PubMed:
Cedrin identified from Cedrus deodara (Roxb.) G. Don protects PC12 cells against neurotoxicity induced by Aβ1-42.
PubMed:
Pretreatment with estrogen does not affect IVF-ICSI cycle outcome compared with no pretreatment in GnRH antagonist protocol: a prospective randomized trial.
PubMed:
[Predictive factors of success in ovulation induction with recombinant FSH: results of Indigo study].
PubMed:
Effects of oral contraceptive, synthetic progestogen or natural estrogen pre-treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol.
PubMed:
Timing of FSH administration for ovarian stimulation in normo-ovulatory women: comparison of an early or a mid follicular phase initiation of a short-term treatment.
PubMed:
[Against the use of clomiphene citrate for unexplained infertilities].
PubMed:
Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study.
PubMed:
[Amenorrhoea].
PubMed:
Beneficial effects of GnRH agonist administration prior to ovarian stimulation for patients with a short follicular phase.
PubMed:
Clinical efficacy and safety of low-dose flutamide alone and combined with an oral contraceptive for the treatment of idiopathic hirsutism.
PubMed:
Phasic serum lipid excursions occur during cyclical oral conjugated oestrogens but not during transdermal oestradiol sequentially combined with oral medroxyprogesterone acetate.
PubMed:
Serum FSH bioactivity and response to acute gonadotrophin releasing hormone (GnRH) agonist stimulation in patients with polycystic ovary syndrome (PCOS) as compared to control groups.
PubMed:
Correlation between selective inhibition of the cyclic nucleotide phosphodiesterases and the contractile activity in human pregnant myometrium near term.
PubMed:
Dihydroflavanonols from Cedrus deodara, A (13)C NMR study.
PubMed:
[The ingredients of the seed of Simaba cedron Planchon. Part 1. Cedrin].